Abstract
Nuclear factor-κB (NF-κB) has been described as one of the most important molecules linking inflammation to cancer. More recently, it has become clear that NF-κB is also involved in the regulation of immune checkpoint expression. Therapeutic approaches targeting immune checkpoint molecules, enabling the immune system to initiate immune responses against tumor cells, constitute a key breakthrough in cancer treatment. This review discusses recent evidence for an association of NF-κB and immune checkpoint expression and examines the therapeutic potential of inhibitors targeting either NF-κB directly or molecules involved in NF-κB regulation in combination with immune checkpoint blockade.
Keywords:
NF-κB; PD-L1; immune checkpoint expression.
MeSH terms
-
Animals
-
B7-H1 Antigen / metabolism*
-
Cell Line, Tumor
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
-
Cyclooxygenase 2 / metabolism
-
Cyclooxygenase Inhibitors / pharmacology
-
Cytokines / metabolism
-
ErbB Receptors / metabolism
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immune Checkpoint Inhibitors / pharmacology*
-
Inflammation / metabolism*
-
Mice
-
NF-kappa B / metabolism*
-
Neoplasms / metabolism*
-
Pentoxifylline / pharmacology
-
Protein Kinase Inhibitors / pharmacology
-
Protein Processing, Post-Translational
-
Signal Transduction
-
Toll-Like Receptors / metabolism
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
B7-H1 Antigen
-
CD274 protein, human
-
Cyclooxygenase Inhibitors
-
Cytokines
-
Immune Checkpoint Inhibitors
-
NF-kappa B
-
Protein Kinase Inhibitors
-
Toll-Like Receptors
-
Tumor Necrosis Factor-alpha
-
Cyclooxygenase 2
-
ErbB Receptors
-
Cyclin-Dependent Kinase 4
-
Pentoxifylline